Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) is one of the best psychedelic stocks on our list.

TheFly reported on July 7 that Oppenheimer reaffirmed its Outperform rating and $20 price target on CMPS shares following new Phase 3 COMP006 26-week results. The firm stated that the data further support the sustained effectiveness of COMP360 in patients with treatment-resistant depression. Oppenheimer believes the latest findings strengthen the company’s regulatory outlook, including a planned NDA submission in the fourth quarter, while reinforcing the potential for the first FDA approval of a classical psychedelic therapy. The firm also views the stock’s commercial opportunity as not fully reflected in its current valuation ahead of a possible first-half 2027 launch.

On the same day, COMPASS Pathways plc (NASDAQ:CMPS) reported 26-week results from Part B of its ongoing Phase 3 COMP006 study evaluating COMP360 for treatment-resistant depression. The findings showed sustained clinical benefits and confirmed the therapy’s rapid onset of action in a population with long-standing, difficult-to-treat depression. The company said 39% of patients receiving the 25 mg dose achieved a clinically meaningful improvement by Week 6, with benefits generally maintained through Week 26. COMP360 also continued to demonstrate a favorable safety profile.

COMPASS Pathways plc (NASDAQ:CMPS) is a UK-based biotechnology company developing psychedelic-based therapies for mental health disorders. Its lead candidate, COMP360, is a synthetic psilocybin treatment combined with psychological support for treatment-resistant depression.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.